To observe the clinical effect of Xiaoyaowan and Guipiwan in treating sub-threshold depression of liver qi stagnation and spleen deficiency and heart-spleen dual deficiency syndrome in older people. Methods:Using prospective research method to collect sample and using DSM-IV, HAMD-17, CES-D and TCM syndrome differentiation method to screen out sub-threshold depression older people with liver qi stagnation and spleen deficiency and heart-spleen dual deficiency syndrome. Then randomly selected 30 people into the blank control group, and divided other cases in to two groups(Guipiwan group and Xiaoyaowan group) according to the two types, with 30 cases in each. Compare the results after treatment. Results:1) After 12 weeks, the total effective rate of Guipiwan group and Xiaoyaowan group are significantly higher than that of the blank control group, while no difference was found between Guipiwan group and Xiaoyaowan group (P>0.05). 2) After 4 weeks, the HAMD-17 score of Guipiwan group and Xiaoyaowan group began to show significant difference with the blank control group(P<0.05), while no difference was found between the two groups. Conclusion:1) Guipiwan and Xiaoyaowan can be used in treating sub-threshold depression in older people, and the effect started to show from the fourth week of treatment. 2) Guipiwan and Xiaoyaowan can also prevent senile dementia, which can be used in the prevention of the disease.